Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer.

阅读:1
作者:Bernstein Aaron J, Keeman Renske, Hurson Amber N, Blows Fiona M, Bolla Manjeet K, Miller Jodi L, Milne Roger L, Horlings Hugo, van den Broek Alexandra J, Bodelon Clara, Hodge James M, Patel Alpa V, Teras Lauren R, Canzian Federico, Kaaks Rudolf, Brenner Hermann, Schöttker Ben, Behrens Sabine, Chang-Claude Jenny, Maurer Tabea, Obi Nadia, Couch Fergus J, Ali H Raza, Caldas Carlos, Andrulis Irene, Glendon Gord, Mulligan Anna Marie, Mesker Wilma, Jager Agnes, Heemskerk-Gerritsen Annette, Devilee Peter, Lawrence Scott M, Lissowska Jolanta, Mutreja Karun, Ahearn Thomas, Chanock Stephen, Duggan Maire A, Eccles Diana, Jones J Louise, Tapper Will, Hollestelle Antoinette, Hooning Maartje, Martens John, van Deurzen Carolien H M, Cox Angela, Cross Simon S, Hartman Mikael, Li Jingmei, Putti Thomas C, Hamann Ute, Rashid Muhammad, Jakubowska Ania, Camp Nicki, Cessna Melissa H, Berrington de Gonzalez Amy, Bialkowska Katarzyna, Gronwald Jacek, Lubiński Jan, Yadav Siddhartha, Lio Pietro, Easton Douglas F, Abubakar Mustapha, Garcia-Closas Montse, Pharoah Paul D P, Schmidt Marjanka K
Breast cancer immune response is important to patient outcome, but the prognostic interaction between tissue-infiltrating immune cell (TIIC) types is not well-characterized. We evaluated the associations between CD8(+), FOXP3+, CD20(+), and CD163(+) TIICs and breast cancer-specific survival (BCSS). We developed an AI in Halo to score TIIC percentage by compartment (overall, stromal, or intra-tumoral) in 99,051 microarray images from 12,285 female breast cancers. The associations between log-transformed TIIC scores and BCSS were assessed using Cox regression. CD8(+) and FOXP3+ TIICs were associated with better BCSS in ER-negative disease; CD8(+) and CD20(+) TIICs were associated with a better prognosis in ER-positive disease; and CD163(+) TIICs were associated with a poorer prognosis in ER-positive disease in multi-marker models. These results may have implications for breast cancer immunotherapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。